Conatus sinks after NASH therapy misses fibrosis endpoint

Conatus lost $1.49 (51%) to $1.42 in after-hours trading Thursday after reporting that emricasan missed the primary endpoint in the Phase IIb ENCORE-NF to treat non-alcoholic

Read the full 266 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE